US medtech company raises US$25m to drive innovation in women’s healthcare

The US medtech company Rejoni has closed a US$25m Series B funding round to accelerate innovation women’s healthcare.

Rejoni, a privately held medtech company based in Massachusetts, is developing gynaecological products with the aim to improve women’s healthcare.

Its first product, Juveena Hydrogel System (HS), is currently undergoing clinical investigation under an IDE pivotal study in the US.

The Juveena HS is being developed for use as a temporary implant to prevent the intrauterine adhesions (IUA) that can form inside the uterine cavity following transcervical gynaecological procedures.

The proceeds from the new round, led by Catalyst Health Ventures, with support from Ascension Health Ventures, Delos Capital, Sparta Group, Amed Ventures and Iyengar Capital Partners, will be used to complete the study and explore additional therapeutic indications in women’s health.

“We recently began enrolling our first patients in the Juveena HS pivotal study and this capital will allow us to complete the study and to build a robust pipeline of differentiated and innovative products,” said Amar Sawhney, CEO of Rejoni.

“We welcome the support of our new and existing investors and look forward to bringing Juveena and other much-needed therapies to the gynaecological community.”

Darshana Zaveri, founder and managing partner at Catalyst Health Ventures, who will also be joining Rejoni’s board of directors, added: “The women’s health market is in severe need for innovative therapies and has been underserved for too long.

“We are excited to support the experienced, talented team at Rejoni in developing a remarkable portfolio of products addressing major unmet needs in gynaecological surgery.”